SEC Tracker
Get the app

Kymera Therapeutics KYMR

Esposito Pamela (Director) plans to sell 27,563 KYMR shares, about $2.3M

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Dec 17, 2025
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Exercise of Stock Options
  4. 10b5-1 plan adopted: Sep 17, 2025

All of Esposito Pamela's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 14,505 shares at $81.56 on Dec 17, 2025 · Form 4
  • Sold 7,959 shares at $82.34 on Dec 17, 2025 · Form 4
  • Sold 4,099 shares at $83.45 on Dec 17, 2025 · Form 4
  • Sold 1,000 shares at $84.07 on Dec 17, 2025 · Form 4
  • Sold 200 shares at $68.52 on Jan 20, 2026 · Form 4

Written from the Form 144 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Kymera Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Acadia Pharmaceuticals ACAD public float $2.3B, Jun 30, 2025
  2. Twist Bioscience TWST public float $2.3B, Mar 31, 2025, over 18 months old
  3. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
  4. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  5. Cytokinetics CYTK public float $2.5B, Jun 30, 2025